C3PO

Condition: COVID-19

Eligibility

Key Inclusion Criteria:

  • Emergency Department patient who:
    • Has one or more symptoms of COVID-19 illness and laboratory
    • Confirmed SARS-CoV-2 infection
    • Has at least one risk factor for severe COVID-19 illness
    • Is stable for outpatient management without supplemental oxygen
       

Key Exclusion Criteria:

  • Less than 18 years old
  • Prior adverse reaction(s) from blood product transfusion
  • Receipt of any blood product within the past 120 days
     

Study Name:

Clinical Trial of COVID-19 Convalescent Plasma in Outpatients: A Multicenter, Two-Arm, Randomized, Single-Blind Clinical Trial to Determine if Receiving One Dose of Convalescent Plasma (CP) for Mild COVID-19 Illness Prevents Illness Progression (IRB no. 00000891)

Summary

The purpose of this study is to determine whether giving convalescent plasma (CP) to individuals with mild COVID-19 illness can prevent progression to severe illness that requires hospital admission. Convalescent plasma (CP) is made from the blood of individuals who have recovered from COVID-19; it contains proteins that may fight COVID-19 infection (antibodies). The antibodies may also protect participants from becoming infected with the virus again. The use of CP for COVID-19 illness is investigational. Participants will be randomly assigned to receive either CP or placebo (inactive substance).

Principal Investigator
Contact

Pulmonary Research Team
310-423-8474
GroupLungResearch@cshs.org